One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™

General Information

Summary The purpose of this trial is to evaluate the long-term safety in subjects previously implanted with VC-01™ combination product.
Clinical trials phase Long term follow up
Start date (estimated) 2016-11-07
End date (estimated) 2023-11-30
Clinical feature
Label type 1 diabetes mellitus
Description A diabetes mellitus that is characterized by destruction of pancreatic beta cells resulting in absent or extremely low insulin production.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT02939118
ICTRP weblink
Other study identifiers
Name VC01-201
Source weblink
Public contact
Public email
United States
Sponsors ViaCyte


Source pluripotent stem cell lines
Which differentiated cell type is used
Label progenitor cell of endocrine pancreas
Description A progenitor cell that is able to differentiate into the pancreas alpha, beta and delta endocrine cells. This cell type expresses neurogenin-3 and Isl-1.


Recruitment Status Enrolling by invitation
Estimated number of participants 200